1
|
Holmgren L, Ambrosino E, Birot O, Tullus C, Veitonmäki N, Levchenko T, Carlson LM, Musiani P, Iezzi M, Curcio C, Forni G, Cavallo F, Kiessling R. A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth. Proc Natl Acad Sci U S A 2006; 103:9208-13. [PMID: 16754857 PMCID: PMC1482591 DOI: 10.1073/pnas.0603110103] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Endogenous angiogenesis inhibitors have shown promise in preclinical trials, but clinical use has been hindered by low half-life in circulation and high production costs. Here, we describe a strategy that targets the angiostatin receptor angiomotin (Amot) by DNA vaccination. The vaccination procedure generated antibodies that detected Amot on the endothelial cell surface. Purified Ig bound to the endothelial cell membrane and inhibited endothelial cell migration. In vivo, DNA vaccination blocked angiogenesis in the matrigel plug assay and prevented growth of transplanted tumors for up to 150 days. We further demonstrate that a combination of DNA vaccines encoding Amot and the extracellular and transmembrane domains of the human EGF receptor 2 (Her-2)/neu oncogene inhibited breast cancer progression and impaired tumor vascularization in Her-2/neu transgenic mice. No toxicity or impairment of normal blood vessels could be detected. This work shows that DNA vaccination targeting Amot may be used to mimic the effect of angiostatin.
Collapse
Affiliation(s)
- Lars Holmgren
- *Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institutet, SE171 76 Stockholm, Sweden
| | - Elena Ambrosino
- Department of Clinical and Biological Sciences, University of Turin, I-10043 Orbassano, Italy
| | - Olivier Birot
- *Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institutet, SE171 76 Stockholm, Sweden
| | - Carl Tullus
- *Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institutet, SE171 76 Stockholm, Sweden
| | - Niina Veitonmäki
- *Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institutet, SE171 76 Stockholm, Sweden
| | - Tetyana Levchenko
- *Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institutet, SE171 76 Stockholm, Sweden
| | - Lena-Maria Carlson
- *Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institutet, SE171 76 Stockholm, Sweden
| | - Piero Musiani
- Aging Research Center, “Gabriele d’Annunzio” University Foundation, I-66013 Chieti, Italy; and
| | - Manuela Iezzi
- Aging Research Center, “Gabriele d’Annunzio” University Foundation, I-66013 Chieti, Italy; and
| | - Claudia Curcio
- Department of Clinical and Biological Sciences, University of Turin, I-10043 Orbassano, Italy
| | - Guido Forni
- Department of Clinical and Biological Sciences, University of Turin, I-10043 Orbassano, Italy
- Molecular Biotechnology Center, University of Turin, I-10123 Turino, Italy
| | - Federica Cavallo
- Department of Clinical and Biological Sciences, University of Turin, I-10043 Orbassano, Italy
- To whom correspondence should be addressed. E-mail:
| | - Rolf Kiessling
- *Department of Oncology and Pathology, Cancer Centre Karolinska, Karolinska Institutet, SE171 76 Stockholm, Sweden
| |
Collapse
|
2
|
Tegerstedt K, Lindencrona JA, Curcio C, Andreasson K, Tullus C, Forni G, Dalianis T, Kiessling R, Ramqvist T. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res 2005; 65:5953-7. [PMID: 15994974 DOI: 10.1158/0008-5472.can-05-0335] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Murine polyomavirus (MPyV) VP1 virus-like particles (VLPs), containing a fusion protein between MPyV VP2 and the extracellular and transmembrane domain of HER-2/neu (Her2), Her2(1-683)PyVLPs, were tested for their ability to vaccinate against Her2-expressing tumors in two different in vivo models. Protection was assessed both against a lethal challenge with a BALB/c mammary carcinoma transfected with human Her2 (D2F2/E2) and against the outgrowth of autochthonous mammary carcinomas in BALB-neuT mice, transgenic for the activated rat Her2 oncogene. A single injection of Her2(1-683)PyVLPs before tumor inoculation induced a complete rejection of D2F2/E2 tumor cells in BALB/c mice. Similarly, a single injection of Her2(1-683)PyVLPs at 6 weeks of age protected BALB-neuT mice with atypical hyperplasia from a later outgrowth of mammary carcinomas, whereas all controls developed palpable tumors in all mammary glands. VLPs containing only VP1 and VP2 did not induce protection. The protection elicited by Her2(1-683)PyVLPs vaccination was most likely due to a cellular immune response because a Her2-specific response was shown in an ELISPOT assay, whereas antibodies against Her2 were not detected in any of the two models. The results show the feasibility of using MPyV-VLPs carrying Her2 fusion proteins as safe and efficient vaccines against Her2-expressing tumors.
Collapse
Affiliation(s)
- Karin Tegerstedt
- Department of Oncology-Pathology, Karolinska Institutet, Cancer Centrum Karolinska, Stockholm, Sweden
| | | | | | | | | | | | | | | | | |
Collapse
|